KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Arbutus Biopharma (ABUS) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Arbutus Biopharma (ABUS) over the last 17 years, with Q3 2025 value amounting to 1452.55%.

  • Arbutus Biopharma's EBITDA Margin rose 36800.0% to 1452.55% in Q3 2025 from the same period last year, while for Sep 2025 it was 289.72%, marking a year-over-year increase of 8361500.0%. This contributed to the annual value of 1128.41% for FY2024, which is 7382300.0% down from last year.
  • As of Q3 2025, Arbutus Biopharma's EBITDA Margin stood at 1452.55%, which was up 36800.0% from 23.3% recorded in Q2 2025.
  • In the past 5 years, Arbutus Biopharma's EBITDA Margin ranged from a high of 23.3% in Q2 2025 and a low of 1456.24% during Q3 2024
  • In the last 5 years, Arbutus Biopharma's EBITDA Margin had a median value of 669.65% in 2021 and averaged 685.34%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first plummeted by -10371700bps in 2024, then surged by 11665800bps in 2025.
  • Quarter analysis of 5 years shows Arbutus Biopharma's EBITDA Margin stood at 669.65% in 2021, then surged by 49bps to 342.93% in 2022, then tumbled by -156bps to 878.74% in 2023, then grew by 9bps to 799.05% in 2024, then plummeted by -82bps to 1452.55% in 2025.
  • Its EBITDA Margin was 1452.55% in Q3 2025, compared to 23.3% in Q2 2025 and 1392.12% in Q1 2025.